REFERENCES
- Mayer S, Brun NC, Begtrup K, et al. Recombinant activated factor Vila for intracerebral hemorrhage. N Engll Med. 2005;352:777–785.
- Mayer S, Brun N, Begtrup K, et al. FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. New Engl I Med. 2008;358:2127–2137.
- Mayer S, Davis S, Skolnick B, et al. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated Factor VII? Stroke. 2009;40:833–840.
- Broderick J, Brott T, Duldner J, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24(7):987–993.
- Counsell C, Boonyakarnkul S, Dennis M, et al. Primary intracerebral hemorrhage in the Oxfordshire Community Stroke Project II. Prognosis. Cerebrovasc Dis. 1995;5:26–34.
- Menikoff J. The hidden alternative: getting investigational treatments off-study. Lancet. 2003;361(9351):63–67.
- Resnik D, Peddada S, Altilio J, Wang N, Menikoff J. Oncology consent forms: failure to disclose off-site treatment availability. IRB. 2008;30(6):7–11.
- Roberts I, Yates D, Sandercock P., et al; CRASH trial collaborators. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364(9442):1321–1328.
- Albrecht T, Blanchard C, Ruckdeschel J. Strategic physician communication and oncology clinical trials. I Clin Oncol. 1999;17:3324–3332.
- Concato J, Horwitz R. Beyond randomised versus observational studies. Lancet. 2004;363 (9422): 1660–1661.
- Angell M. Patients' preferences in randomized clinical trials. N Engl I Med. 1984;310(21):1385–1387.
- Schafer A. The ethics of the randomized controlled trial. N Engll Med. 1982;307:719–724.
- Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl I Med. 2000;342(25):1887–1892.